The Amgen drug is currently approved for adults in the advanced stages of small cell lung cancer that has worsened despite chemotherapy, based on data showing that Imdelltra reduced the risk of death by 40%. Amgen’s Imdelltra plus Imfinzi improves survival in extensive-stage small cell lung cancer, outperforming Imfinzi alone in a pivotal trial.